InvestorsHub Logo
icon url

sojourner

11/05/10 4:00 PM

#34675 RE: Wales Walker #34673

Re: "We have a license agreement with the inventors in Ukraine."

As points of clarification, who is the owner, who is the licensor, and who is the licensee of inventor Paton's patents? Live Tissue Connect, Inc. is named as the assignee of the two U.S. patents below. What are the terms of the license agreement(s)? Who owns Live Tissue Connect, Inc. and in what proportion?

http://www.google.com/patents/about?id=Ig4QAAAAEBAJ&dq=%22live+tissue+connect%22

1) System and method for control of tissue welding
Inventors: Boris E. Paton, Vladimir K. Lebedev, Alexei V. Lebedev, Yurii A. Masalov, Olga N. Ivanova, Mykhailo P. Zakharash, Yuri A. Furmanov
Assignees: Live Tissue Connect, Inc.
Patent number: 6733498
Filing date: Feb 19, 2002
Issue date: May 11, 2004

http://www.google.com/patents/about?id=IHx3AAAAEBAJ&dq=%22live+tissue+connect%22

2) Bonding of soft biological tissues by passing high frequency electric therethrough
Inventors: Boris E. Paton, Vladimir K. Lebedev, David S. Vorona, Volodimir I. Karchemsky, Yuri A. Furmanov, Alexsey V. Lebedev, Valery A. Vasilchenko, Dmitry F. Sidorenko, Vitaly P. Iemchenko-Ribko, Olga N. Ivanova, Alexandr Y. Furmanov, Yevgen V. Zhyvodernikov, Andrei A. Lyashenko, Irina M. Savitskaya
Assignees: Live Tissue Connect, Inc.
Patent number: 7025764
Filing date: Dec 4, 2002
Issue date: Apr 11, 2006


ctgi
icon url

abbam

11/05/10 4:31 PM

#34676 RE: Wales Walker #34673

Bruce,

you mentioned on the call a minimum investment. How much is the min ?
icon url

sojourner

11/05/10 5:22 PM

#34678 RE: Wales Walker #34673

Re: "...whatever the final share structure, will be diluted along with everyone else - no sweet deal for insiders."

From that statement one may infer that dilution, as now more than implied, will be a bitter deal for all stockholders. I agree. There are likely no choices that will not cream existing shareholders which is precisely why buying now in the midst of swirling uncertainties and bloodletting reversals poses a significant risk. When a firm is starving for funds, watch out below. In any case, it doesn't negate my opinion that "the managers and directors will carve a niche for themselves in the new incarnation." Not that I would blame them!

ctgi